Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international ...

It would work, for a while, and she would lose some weight. Ultimately, however, “I couldn’t get over the obsession with food ...

Once scorned as a cosmetic lifestyle disfigurement, obesity today is recognised as a chronic and progressive disease. From the altered metabolic deran.

For adults with type 2 diabetes and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality.